Crossref
Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML
The Journal of Community and Supportive Oncology · 2013
DOI: 10.12788/j.cmonc.0046 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Matt Kalaycio.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kalaycio, M. (2013). Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0046
Vancouver
Kalaycio M. Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0046
BibTeX
@article{Kalaycio2013,
author = {Kalaycio, Matt},
title = {Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML},
journal = {The Journal of Community and Supportive Oncology},
year = {2013},
doi = {10.12788/j.cmonc.0046}
}
EUVIMED